BMTCN Test A Latest Update -

BMTCN Test A Latest Update - Exam from Credible Sources with 50 Questions and Verified Correct Answers Golden Ticket to Guaranteed A+ Verified by Professor

A patient had an allogeneic HSCT three years ago and now has type 4 posttransplant lymphoproliferative disease. How should the patient be treated?

• Reduction of immunosuppressants
• Aggressive chemotherapy
• No interventions needed

D. Increased Immunosuppressants - CORRECT ANSWER: B. Aggressive

chemotherapy

Type 4 PTLD treated with aggressive chemotherapy has a good prognosis.

A patient reports facial swelling during the stem cell infusion. The nurse should immediately stop the infusion and anticipate an order for which medication?

• Cryotherapy
• Furosemide
• Antihistamines

D. Oxygen - CORRECT ANSWER: C. Antihistamines

Urticaria, pruritus, facial or glottal edema are all signs of an allergic reaction. The nurse should stop the infusion and then administer antihistamines.

A patient should be instructed to manage oral mucositis by:

• / 3

• rinsing the mouth frequently with sodium bicarbonate.
• requesting a prescription for "magic mouthwash".
• using hydrogen peroxide rinses if there are no open lesions.
• requesting a prescription for acyclovir rinses. - CORRECT ANSWER: A. rinsing the

mouth frequently with sodium bicarbonate.

The goals of mouth care and oral rinses with saline are to remove oral debris and microorganisms, provide mucosal hydration, and decrease inflammation and pain.

A patient who is diagnosed with acute myeloid leukemia two years after treatment for neuroblastoma is being evaluated for an allogeneic HSCT. Which medication most likely contributed to the secondary malignancy?

• Cisplatin
• Fludarabine
• Cytarabine

D. Etoposide - CORRECT ANSWER: D. Etoposide

Topoisomerase II inhibitor-related AML usually appears 2-3 years after exposure to the drug. Etoposide is a topoisomerase II inhibitor.

A patient who received high-dose cyclophosphamide two days ago is now experiencing dyspnea, chest pain, orthopnea, cough, fever, and tachycardia. Which of the following is the patient most likely experiencing?

• Paraneoplastic syndrome
• Cardiotoxicity
• Pulmonary embolism

D. Hyperthyroidism - CORRECT ANSWER: B. Cardiotoxicity

• / 3

Cyclophosphamide cardiotoxicity presents with dyspnea, pleuritic chest pain, orthopnea, cough, fever, and tachycardia.

A patient with an overall grade +3 for acute graft-versus-host disease has a bilirubin

level of:

• >15 mg/dL
• 2-3 mg/dL
• 3.1-6 mg/dL

D. 6.1-15 mg/dL - CORRECT ANSWER: D. 6.1-15 mg/dL

A patient with grade +3 for acute GVHD has a bilirubin level of 6.1-15 mg/dL.

A patient with lymphoma who received an HSCT has heart failure and arrhythmias. The

most likely cause is:

• sirolimus.
• high-dose cyclophosphamide.
• cyclosporine.

D. long-term immunosuppressants. - CORRECT ANSWER: B. high-dose

cyclophosphamide.

High dose cyclophosphamide can cause cardiac side effects.

A pre-transplant patient asks about ABO compatibility with the donor. The nurse

explains that:

• there is less risk of GVHD.
• the likelihood of engraftment is increased.
• it is not essential for success.
• / 3